Petra Kleinbongard

Prof. Dr. Petra Kleinbongard

Institute of Pathophysiology, Clinic for Cardiology, West German Heart and Vascular Centre Essen, University of Essen Medical School, Hufelandstraße 55, 45122 Essen, Germany
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2016 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
Petra KleinbongardPetra Kleinbongard
Petra Kleinbongard
ASAndreas Skyschally
Andreas Skyschally
GHGerd Heusch
Gerd Heusch

25 July 2022 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
Mariann GyöngyösiMariann Gyöngyösi
Mariann Gyöngyösi
PAPilar Alcaide
Pilar Alcaide
FAFolkert W Asselbergs
Folkert W Asselbergs
BBBianca J J M Brundel
Bianca J J M Brundel
GCGiovanni G Camici
Giovanni G Camici
SDSean M Davidson
Sean M Davidson
Long COVID has become a world-wide, non-communicable epidemic, caused by long-lasting multiorgan symptoms that endure for weeks or months after SARS-CoV-2 infection has already subsided. This scientific document aims to provide insight into the possible causes and therapeutic options available for the cardiovascular manifestations of long COVID. In addition to chronic fatigue, which is a common symptom of long COVID, patients may present with chest pain, ECG abnormalities, postural orthostatic tachycardia, or newly developed supraventricular or ventricular arrhythmias. Imaging of the heart and vessels has provided evidence of chronic, post-infectious perimyocarditis with consequent left or right ventricular failure, arterial wall inflammation, or microthrombosis in certain patient populations. Better understanding of the underlying cellular and molecular mechanisms of long COVID will aid in the development of effective treatment strategies for its cardiovascular manifestations. A number of mechanisms have been proposed, including those involving direct effects on the myocardium, microthrombotic damage to vessels or endothelium, or persistent inflammation. Unfortunately, existing circulating biomarkers, coagulation, and inflammatory markers, are not highly predictive for either the presence or outcome of long COVID when measured 3 months after SARS-CoV-2 infection. Further studies are needed to understand underlying mechanisms, identify specific biomarkers, and guide future preventive strategies or treatments to address long COVID and its cardiovascular sequelae.

16 November 2021 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
Petra KleinbongardPetra Kleinbongard
Petra Kleinbongard
GHGerd Heusch
Gerd Heusch

1 December 2021 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
Merry L LindseyMerry L Lindsey
Merry L Lindsey
KBKeith R. Brunt
Keith R. Brunt
JKJonathan A. Kirk
Jonathan A. Kirk
Petra KleinbongardPetra Kleinbongard
Petra Kleinbongard
JCJohn W. Calvert
John W. Calvert
ZKZamaneh Kassiri
Zamaneh Kassiri
Despite significant improvements in reperfusion strategies, acute coronary syndromes all too often culminate in a myocardial infarction (MI). The consequent MI can, in turn, lead to remodeling of the left ventricle (LV), the development of LV dysfunction, and ultimately progression to heart failure (HF). Accordingly, an improved understanding of the underlying mechanisms of MI remodeling and progression to HF is necessary. One common approach to examine MI pathology is with murine models that recapitulate components of the clinical context of acute coronary syndrome and subsequent MI. We evaluated the different approaches used to produce MI in mouse models and identified opportunities to consolidate methods, recognizing that reperfused and nonreperfused MI yield different responses. The overall goal in compiling this consensus statement is to unify best practices regarding mouse MI models to improve interpretation and allow comparative examination across studies and laboratories. These guidelines will help to establish rigor and reproducibility and provide increased potential for clinical translation. Listen to another corresponding podcast at https://ajpheart.podbean.com/e/guidelines-for-in-vivo-mouse-models-of-myocardial-infarction/ .

21 July 2015 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
Petra KleinbongardPetra Kleinbongard
Petra Kleinbongard
NGN Gedik
N Gedik
Paul WittingPaul Witting
Paul Witting
BFB Freedman
B Freedman
NKN Klöcker
N Klöcker
GHG Heusch
G Heusch

1 November 2021 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
Merry L LindseyMerry L Lindsey
Merry L Lindsey
ALAmanda J. LeBlanc
Amanda J. LeBlanc
CRCrystal M. Ripplinger
Crystal M. Ripplinger
JCJason R. Carter
Jason R. Carter
JKJonathan A. Kirk
Jonathan A. Kirk
ZKZamaneh Kassiri
Zamaneh Kassiri